title
Resolution providing for the creation of the Opioid Misuse Abatement Trust Fund and setting conditions for the deposit and expenditures from said trust fund.
body
WHEREAS, following settlement in litigation at City of Pittsburgh v. Purdue Pharma, L.P. et al., Case No. 18-006153, as coordinated in In Re Opioid Litigation, No. 2017-00895 (Delaware County, PA) stemming from In Re: National Prescription Opiate Litigation Case No. 1:17-md-2804 in the US District Court for the Northern District of Ohio, MDL 2804 initially as to the Defendants McKesson Corporation, Cardinal Health, Inc. and AmeriSource Bergen Corporation, Johnson and Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc., and related litigation, parties have agreed to a settlement of claims wherein the Pennsylvania Opioid Misuse and Addiction Abatement Trust shall receive settlement funds, hold such funds until payment, and then disburse such funds pursuant to the terms and conditions set forth in Pennsylvania's Intrastate Opioid Trust & Allocation Order;
WHEREAS, the City of Pittsburgh was authorized to enter into this settlement pursuant to Resolution 123 of 2022, effective March 30, 2022.
WHEREAS, the Pennsylvania Opioid Misuse and Addiction Abatement Trust is set to provide approximately eighteen years of fiscal aid to Counties and Municipalities throughout Pennsylvania to aid in opioid misuse abatement;
WHEREAS, the City of Pittsburgh will receive these future direct payments as directed by Pennsylvania's Intrastate Opioid Trust & Allocation Order previously authorized by the parties;
WHEREAS, monies deposited will be allocated to the City pursuant to the formula set forth in Pennsylvania's Intrastate Opioid Trust & Allocation Order, less costs associated with administration of the Pennsylvania's Opioid Misuse and Addiction Abatement Trust;
WHEREAS, the City will spend funds from this settlement in accordance with the purposes of...
Click here for full text